Monitoring serum vancomycin concentrations in the treatment of Staphylococcus infections in children;Surveillance des taux sériques de vancomycine dans le traitement des infections à staphylocoque en pédiatrie

Archives de Pediatrie

Volumn 15, Issue 11, 2008, Pages 1625-1629

  Mariani Kurkdjian, P ^a   Nebbad, H ^b   Aujard, Y ^a   Bingen, E ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ARTICLE; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; EPSILOMETER TEST; FLUORESCENCE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; HUMANS; INFANT; INFANT, NEWBORN; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 55349087529     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2008.08.016     Document Type: Article

References (29)

1. Raymond J., Nordmann P., Doit C., et al. Multidrug-resistant bacteria in hospitalized children: a 5-year multicenter study. Pediatrics 119 (2007) e798-e803
2. Tristan A., Ferry T., Durand G., et al. Virulence determinants in community and hospital methicillin-resistant Staphylococcus aureus. J Hosp Infect 65 (2007) 105-109
3. Seay R.E., Brundage R.C., Jensen P.D., et al. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther 56 (1994) 169-175
4. Tan W.H., Brown N., Kelsall A.W., et al. Dose regimen for vancomycin not needing serum peak levels. Arch Dis Child Fetal Neonatal Ed 87 (2002) F214-F216
5. Mellor J.A., Kingdom J., Cafferkey M., et al. Vancomycin toxicity: a prospective study. J Antimicrob Chemother 15 (1985) 773-780
6. Zimmermann A.E., Katona B.G., and Plaisance K.I. Association of vancomycin concentrations with outcome in patients with Gram-positive bacteraemia. Pharmacotherapy 15 (1995) 85-91
7. Bhatt-Mehta V., Schumacher R.E., Faix R.G., et al. Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study. Pediatrics 103 (1999) e48
8. MacGowan A.P. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 20 (1998) 473-477
9. MacGowan A.P., White L., Reeves D., et al. Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome. J Infect Chemother 2 (1996) 197-208
10. LaPlante K.L., and Rybak M.J. Impact of high-inoculum Staphylococcus aureus on the activities of nafcilllin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 48 (2004) 4665-4672
11. Mercier R.C., Stumpo C., and Rybak M.J. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY 333328), against Staphylococcus aureus and Enterococcus faecium. J Antimicrob Chemother 50 (2002) 19-24
12. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 29-35
13. Carbon C. Impact of the antibiotic dosage schedule on efficacy in experimental endocarditis. Scand J Infect Dis 74 (1990) 163-172
14. Rybak M.J., and Boike S.C. Monitoring vancomycin therapy. Drug Intell Clin Pharm 20 (1986) 757-761
15. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 1 (2001) 147-155
16. Mulhern J.G., Braden G.L., O'Shea M.H., et al. Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. Am J Kidney Dis 25 (1995) 611-615
17. Potel G., Caillon J., Jacqueline C., et al. Dosage des antibiotiques en réanimation : quand et comment demander et interpréter les tests ?. Reanimation 15 (2006) 187-192
18. Rybak M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 42 (2006) S35-S39
19. Hartman B.J., Kaplan S.L., Kaufman B.A., et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39 (2004) 1267-1284
20. Hidayat L.K., Hsu D.K., Quist R., et al. A high-dose vancomycin therapy for meticillin-resistant Staphylococcus aureus infections. Arch Intern Med 166 (2006) 2138-2144
21. Goldstein F.W., and Kitzis M.D. Vancomycin-resistant Staphylococcus aureus: no apocalyse now. Clin Microb Infect 9 (2003) 761-765
22. Wysocki M., Delatour F., Faurisson F., et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 45 (2001) 2460-2467
23. Sakoulas G., Moise-Broder P.A., Schentag J.J., et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42 (2004) 2398-2402
24. Maclayton D.O., Suda K.J., Colval K.A., et al. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 μg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther 28 (2006) 1208-1216
25. Hyatt J.M., Nix D.E., and Schentag J.J. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MIC are similar. Antimicrob Agents Chemother 38 (1994) 2730-2737
26. Moise P.A., Forrest A., Birmingham M.C., et al. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to vancomycin. J Antimicrob Chemother 50 (2002) 1017-1026
27. Garaffo R., and Lavrut T. Signification clinique des corrélations pharmacocinétique/pharmacodynamie des antibiotiques chez les patients de réanimation. Reanimation 14 (2005) 264-275
28. Kitzis M.D. Dosage des antibiotiques. In: Courvalin P., Leclercq R., and Bingen E. (Eds). Antibiogramme (2006), ESKA, Paris 653-656
29. Mohr J.F., and Murray B.E. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 44 (2007) 1536-1542